Stocks Health care TBPH
NASDAQ · Health careTheravance Biopharma, Inc. (TBPH)
Theravance Biopharma, Inc. brought in $104.3M of revenue over the twelve months to June 30, 2026, up 35.1% from a year earlier. Net income was $53.8M, a net margin of 51.6%. Operating cash flow minus capital spending left $238.5M of free cash flow in fiscal 2025. At June 30, 2026 it held $219.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
Key facts about Theravance Biopharma, Inc.
- Net worth
- Theravance Biopharma, Inc. has a market value (market cap) of $884.2M at the latest share price, and shareholders' equity of $289.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $107.5M (+66.9% year on year), with net income of $105.9M. Over the 12 months to June 30, 2026: revenue $104.3M, net income $53.8M.
- Cash flow
- In fiscal 2025 operations brought in $238.5M of cash; after $42K of capital spending, free cash flow was $238.5M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 11, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Theravance Biopharma, Inc.'s next report was expected around November 9, 2026 and is not on file with the SEC yet.
What Theravance Biopharma, Inc. does
Theravance Biopharma, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker TBPH.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $107.5M | $105.9M | $2.06 | $238.5M |
| 2024 | $64.4M | -$56.4M | -$1.15 | -$11.9M |
| 2023 | $57.4M | -$55.2M | -$1.00 | -$29.5M |
| 2022 | $51.3M | $872.1M | $11.85 | -$187.6M |
| 2021 | $55.3M | -$199.4M | -$2.87 | -$211.3M |
| 2020 | $71.9M | -$278M | -$4.46 | -$257M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where TBPH ranks in Health care
Latest SEC filings
What Theravance Biopharma, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 5, 2026Deregistration 15-12G
- September 25, 2026Activist stake changed SCHEDULE 13D/A
- September 24, 2026Form S-8 POS filing S-8 POS
- September 24, 2026Form S-8 POS filing S-8 POS
- September 24, 2026Form S-8 POS filing S-8 POS
- September 24, 2026Form S-8 POS filing S-8 POS
- September 24, 2026Form S-8 POS filing S-8 POS
- September 24, 2026Form S-8 POS filing S-8 POS
- September 24, 2026Form S-8 POS filing S-8 POS
- September 24, 2026Form S-8 POS filing S-8 POS
What is TBPH worth? A DCF from its reported cash flow
Insider trades
What the people running Theravance Biopharma, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $226.8K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 23, 2026 | Weiss Asset Management LPFormer 10% Owner | Other changeindirect | 7,457,060 | $126.8M |
| September 23, 2026 | Mitchell Dean JDirector | Other change | 91,204 | - |
| September 23, 2026 | Mitchell Dean JDirector | Other change | 6,009 | - |
| September 23, 2026 | Pakianathan DeepikaDirector | Other change | 58,065 | - |
| September 23, 2026 | Pakianathan DeepikaDirector | Other change | 6,009 | - |
| September 23, 2026 | Winningham Rick ECHIEF EXECUTIVE OFFICER, Director | Other change | 1,382,272 | - |
| September 23, 2026 | Winningham Rick ECHIEF EXECUTIVE OFFICER, Director | Other change | 151,875 | - |
| September 23, 2026 | Winningham Rick ECHIEF EXECUTIVE OFFICER, Director | Other change | 76,875 | - |
Who owns TBPH
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Madison Avenue International LP13G, passive with 5 related filers | 17.7% | August 14, 2026 |
| Newtyn Management, LLC13G, passive with 1 related filers | 6.7% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 181 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Madison Avenue Partners, LP | 9,212,252 | -298,898 |
| Weiss Asset Management LP | 7,457,060 | 0 |
| BlackRock, Inc. | 4,562,487 | +266,197 |
| Newtyn Management, LLC | 3,434,191 | -1,407,438 |
| Irenic Capital Management LP | 2,760,948 | 0 |
| Vanguard Capital Management LLC | 1,771,493 | -12,260 |
| State Street Corp | 1,328,584 | +31,261 |
| Two Sigma Investments, LP | 1,225,587 | -32,910 |
| D. E. Shaw & Co., Inc. | 1,185,390 | +231,348 |
| Geode Capital Management, LLC | 1,117,895 | -19,567 |
| Dimensional Fund Advisors LP | 1,043,051 | +59,436 |
| Mackenzie Financial Corp | 985,848 | +737,166 |
| Morgan Stanley | 705,202 | +194,930 |
| Oasis Management Co Ltd. | 583,490 | 0 |
| Citadel Advisors LLC | 506,668 | +420,577 |
| UBS Group AG | 488,309 | -275,796 |
| Qube Research & Technologies Ltd | 429,813 | +140,340 |
| Northern Trust Corp | 404,356 | +33,822 |
| Vanguard Portfolio Management LLC | 394,158 | -6,601 |
| Jupiter Topco LLC | 387,493 | new |
Insiders
2 insiders reported holding 9,219,156 shares in total, about $157M at the last price.
| Holder | Shares |
|---|---|
| Samaha Eli10% owner | 9,174,4539,174,453 held indirectly |
| Broshy EranDirector | 44,703 |
Questions about TBPH
What does Theravance Biopharma, Inc. do?
Theravance Biopharma, Inc. is a company in the Health care sector, listed on NASDAQ as TBPH. Its shares trade on NASDAQ under the ticker TBPH.
What is Theravance Biopharma, Inc.'s net worth?
Theravance Biopharma, Inc. has a market value (market cap) of $884.2M at the latest share price, and shareholders' equity of $289.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Theravance Biopharma, Inc. profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $53.8M on revenue of $104.3M, a net margin of 51.6%.
How much revenue does Theravance Biopharma, Inc. make?
Over the twelve months to June 30, 2026 Theravance Biopharma, Inc. reported revenue of $104.3M. That is 35.1% more than a year earlier.
When did Theravance Biopharma, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the deregistration from October 5, 2026.
When is Theravance Biopharma, Inc.'s next earnings report?
Theravance Biopharma, Inc.'s next report was expected around November 9, 2026 and is not on file with the SEC yet.
Similar companies
Compare TBPH with
Follow TBPH
Get an email when Theravance Biopharma, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Theravance Biopharma, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.